Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
Seminoma, Testicular Cancer
About this trial
This is an interventional treatment trial for Seminoma focused on measuring Seminoma, Stage IIA/B seminoma, Radio-chemotherapy, Phase II trial, Testicular Cancer
Eligibility Criteria
Inclusion Criteria:
- Written informed consent according to ICH/GCP (International Council on Harmonization/Good Clinical Practice) regulations before registration and prior to any trial specific procedures
- Histologically confirmed classical seminoma treated with primary inguinal orchidectomy or partial orchidectomy
- Patients with a seminoma stage IIA or IIB, either newly diagnosed or recurrent after primary active surveillance, adjuvant carboplatin or radiotherapy for stage I disease. The tumor stage is pT1-4 cN1-2 cM0 according to UICC TNM 8th edition 2016. Patients with a recurrent seminoma stage IIA or IIB are only eligible in case of progression under active surveillance or recurrence after adjuvant carboplatin or radiotherapy for stage I disease
- Stage IIA, in patients with equivocal lymph node enlargement, needs to be confirmed with a repeated CT/MRI scan of the abdomen (suggested timeframe: 4 weeks after the previous scan) in order to rule out false positive lymph node enlargement.
Patients with a prior malignancy treated with curative intention are eligible if all treatment of that malignancy was completed at least 5 years before registration and the patient has no evidence of disease at registration. Less than 5 years is acceptable for malignancies with low risk of recurrence and/or no late recurrence. Patients with a germ cell neoplasia in situ (GCNIS) or contralateral localized treated seminoma are eligible
- Diagnostic CT or MRI or FDG-PET-CT of the chest, abdomen and pelvis within 28 days prior to registration, showing stage IIA/B disease. I.v. contrast medium has to be administered
- Age ≥ 18 years
- WHO performance status 0-2
- Baseline PRO questionnaires have been completed
- Adequate bone marrow function: neutrophil count ≥ 1.0 x 109/L, platelet count ≥ 100x 109/L
- Adequate renal function: creatinine clearance ≥ 60 ml/min calculated according to the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula
- Patient agrees to use highly effective contraception and not to donate sperm or to father a child during trial treatment and during 12 months thereafter. Patient has been proposed sperm conservation.
Exclusion criteria
- Any other histological component than seminoma
- Elevated levels of Alpha-1-Fetoprotein AFP (≥ 2x ULN)
- Involved nodes (metastatic) in previously irradiated localizations in the abdomen or pelvis
- Any anti-cancer therapy after primary tumor resection in patients presenting with primary stage IIA/B seminoma
- Any serious underlying medical condition (i.e. current renal insufficiency, severe hepatic insufficiency, severe bone marrow dysfunction, tumor bleeding, major hearing defects) or serious co-morbidity which could impair the ability of the patient to participate in the trial (according to investigator's judgment)
- Any treatment in a clinical trial within 28 days prior to registration
- Any concomitant drugs contraindicated for use with the trial drugs according to the approved product information or contraindicated for use with radiotherapy
- Known hypersensitivity to trial drugs or to any component of the trial drugs
- Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.
Additional German specific exclusion criteria - not to be considered for Swiss patients
- Patient who is dependent on the sponsor or the investigators according to ICH/GCP E6(R2), guideline
- Patient who has been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities according to § 40a (2) AMG.
Sites / Locations
- Vivantes Klinikum Am Urban
- Helios Klinikum Berlin-Buch
- Evang. Kliniken Essen-Mitte
- Universitätsklinikum Hamburg-Eppendorf
- ASKLEPIOS Kliniken
- RKH Klinikum Ludwigsburg
- Rotkreuzklinikum München
- Universitätsklinikum Tübingen
- Universitätsklinikum Ulm
- Universitaetsspital-Basel
- Istituto Oncologico della Svizzera Italiana (IOSI)
- Inselspital Bern
- Kantonsspital Graubuenden
- Kantonsspital Graubünden
- Centre Hospitalier Universitaire Vaudois CHUV
- Hopital de Sion
- Kantonsspital - St. Gallen
- Kantonsspital Winterthur
- UniversitätsSpital Zürich
Arms of the Study
Arm 1
Experimental
Arm with 2 cohorts
Cohort 1: Primary stage IIA and recurrent stage IIA seminoma after active surveillance for stage I: Within 7 days after registration, the patients will receive one infusion of carboplatin AUC (Area under the curve) 7 at day 1 of trial treatment, followed 3 weeks later by 12 x 2 Gy involved-node radiation therapy (RT). RT should ideally start on day 22 (range: day 19-25) from the date of carboplatin administration, preferably on a Monday. Cohort 2: Primary stage IIB and recurrent stage IIB seminoma after active surveillance for stage I OR stage IIA/B seminoma after adjuvant carboplatin or radiotherapy for stage I: Within 7 days after registration, the patients will receive one cycle of etoposide 100 mg/m2/d + cisplatin 20 mg/m2/d at days 1 to 5 of trial treatment, followed 3 weeks later by 15 x 2 Gy involved-node radiation therapy. RT should ideally start on day 22 (range: day 19-25) from the date of chemotherapy start, preferably on a Monday.